Skip to main content
Body, Mind & Bioethics

Should Psychedelics Be Legal Medicine?

The FDA rejected MDMA therapy in 2024; Phase 2 PTSD trials showed 67% remission. Oregon is running licensed psilocybin clinics. Most promising psychiatric breakthrough in 50 years — or a hype cycle with a blinding problem? Two debaters, opposing sides — you score who makes the stronger case.

What’s at stake

If the evidence holds, 50 years of Schedule I classification was a catastrophic error in medical history. If it doesn't replicate, enormous credibility has been misplaced.

The opposing positions

Resolved: Psilocybin, MDMA, and other psychedelics should be licensed as regulated prescription treatments

Affirmative

The evidence demands access

These compounds have the best treatment-resistant depression and PTSD data in a generation; scheduling them as Schedule I while fentanyl kills 100,000 Americans per year is a policy failure with a body count.

Read the affirmative case
  • Phase 2 MAPS trials showed 67% of MDMA-treated PTSD patients no longer met the diagnostic criteria at 12 months, a remission rate no existing treatment approaches, and psilocybin trials at Johns Hopkins and NYU show comparable results for treatment-resistant depression.
  • Psilocybin mushrooms, peyote, and ayahuasca each have a documented history of safe ceremonial and therapeutic use spanning millennia; the unknown-risk framing applies to rapid pharmaceutical commercialization, not the substances themselves.
  • The FDA's 2024 rejection was based on trial-design concerns, not evidence of harm; the solution is a clear licensing pathway with rigorous therapist certification requirements, not continued prohibition of the most promising psychiatric drug class in 50 years.

Negative

The hype has outrun the science

The phase-3 trials failed; the blinding problem is structurally unsolvable; and commercializing powerful psychoactive drugs before we understand them is a mistake we will spend decades cleaning up.

Read the negative case
  • The most rigorous MDMA trial, which the FDA reviewed in 2024, showed the drug did not beat placebo in one of two phase-3 studies, with a blinding problem so severe that 'double-blind' is fiction; participants always know they took the drug, making expectancy effects inseparable from pharmacological effects.
  • Psychedelics carry real risks: triggering latent psychosis, cardiac events with MDMA, and serious ethical violations in therapeutic contexts: three therapists in MAPS's own trials were found to have sexually abused patients during or after sessions.
  • The set, setting, and therapeutic relationship appear to drive most of the effect; the commercialization model of brief pill plus minimal therapy strips out what works while profiting from the brand, at the expense of patient safety.

Add your perspective

Record a 60-second response or write an argument. You can contribute without waiting for an opponent.

Write an argument

Responses are public. Share only material you have permission to publish.

Affirmative responses

Negative responses

1 video
0
Read the discussion

How the debate unfolds

Each side makes its case, answers questions and responds to the other’s arguments.

  1. 4 min

    Opening Argument

    PRO · opening case

  2. 4 min

    Cross-Examination

    CON questions PRO

  3. 4 min

    Opening Argument

    CON · opening case

  4. 4 min

    Cross-Examination

    PRO questions CON

  5. 3 min

    Rebuttal

    PRO

  6. 3 min

    Rebuttal

    CON

  7. 3 min

    Closing Statement

    PRO · final case

  8. 3 min

    Closing Statement

    CON · final case

  9. —

    Audience scoring

    Persuasion, evidence, clarity and refutation

Get Involved

Open debate runs on the people who show up. Tell us how you want to be part of it.

I want to…

No spam. We'll only reach out about what you picked.